
A
Agilent Technologies Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
118.050
Open
116.570
VWAP
116.77
Vol
69.87K
Mkt Cap
33.53B
Low
116.540
Amount
8.16M
EV/EBITDA(TTM)
19.50
Total Shares
291.76M
EV
35.54B
EV/OCF(TTM)
22.42
P/S(TTM)
5.11
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
1.76B
+4.93%
1.430
+9.17%
1.77B
+4.08%
1.593
+9.1%
1.66B
+5.45%
1.366
+3.52%
Estimates Revision
The market is revising Upward the revenue expectations for Agilent Technologies, Inc. (A) for FY2025, with the revenue forecasts being adjusted by 0.81% over the past three months. During the same period, the stock price has changed by 9.80%.
Revenue Estimates for FY2025
Revise Upward

+0.81%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.51%
In Past 3 Month
Stock Price
Go Up

+9.80%
In Past 3 Month
13 Analyst Rating

16.58% Upside
Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 136.27 USD with a low forecast of 120.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
0 Sell
Moderate Buy

16.58% Upside
Current: 116.890

Low
120.00
Averages
136.27
High
165.00

16.58% Upside
Current: 116.890

Low
120.00
Averages
136.27
High
165.00
Barclays
Luke Sergott
Equal Weight
maintain
$115 -> $125
2025-06-24
Reason
Barclays
Luke Sergott
Price Target
$115 -> $125
2025-06-24
maintain
Equal Weight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Agilent to $125 from $115 and keeps an Equal Weight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
JPMorgan
Overweight
to
Overweight
downgrade
$160 -> $155
2025-05-29
Reason
JPMorgan
Price Target
$160 -> $155
2025-05-29
downgrade
Overweight
to
Overweight
Reason
JPMorgan lowered the firm's price target on Agilent to $155 from $160 and keeps an Overweight rating on the shares. The company reported a fiscal Q2 beat and reiterated 2025 core revenue growth and earnings guidance, the analyst tells investors in a research note. The firm updated Agilent's forward estimates.
UBS
Dan Leonard
Neutral
downgrade
$150 -> $130
2025-05-29
Reason
UBS
Dan Leonard
Price Target
$150 -> $130
2025-05-29
downgrade
Neutral
Reason
UBS analyst Dan Leonard lowered the firm's price target on Agilent to $130 from $150 and keeps a Neutral rating on the shares. Agilent maintained its outlook despite the "dynamic" macro environment, the analyst tells investors in a research note.
Baird
Outperform -> NULL
downgrade
$159 -> $140
2025-05-22
Reason
Baird
Price Target
$159 -> $140
2025-05-22
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Agilent to $140 from $159 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q2 results.
Jefferies
Brandon Couillard
Hold
Maintains
$135 → $116
2025-04-21
Reason
Jefferies
Brandon Couillard
Price Target
$135 → $116
2025-04-21
Maintains
Hold
Reason
Jefferies lowered the firm's price target on Agilent to $116 from $135 and keeps a Hold rating on the shares after having hosted a call with Simon May and Brian Carothers to discuss the roughly $450M CDMO business. Orders remain "strong" and NASD margins are above corporate average, the analyst tells investors following the management call.
Jefferies
Brandon Couillard
Hold
Maintains
$135 → $116
2025-04-21
Reason
Jefferies
Brandon Couillard
Price Target
$135 → $116
2025-04-21
Maintains
Hold
Reason
Jefferies lowered the firm's price target on Agilent to $116 from $135 and keeps a Hold rating on the shares after having hosted a call with Simon May and Brian Carothers to discuss the roughly $450M CDMO business. Orders remain "strong" and NASD margins are above corporate average, the analyst tells investors following the management call.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Agilent Technologies Inc (A.N) is 20.25, compared to its 5-year average forward P/E of 25.99. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
25.99
Current PE
20.25
Overvalued PE
30.15
Undervalued PE
21.83
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
20.97
Current EV/EBITDA
16.80
Overvalued EV/EBITDA
24.02
Undervalued EV/EBITDA
17.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
5.86
Current PS
4.90
Overvalued PS
6.60
Undervalued PS
5.12
Financials
Annual
Quarterly
FY2025Q2
YoY :
+6.04%
1.67B
Total Revenue
FY2025Q2
YoY :
-2.20%
356.00M
Operating Profit
FY2025Q2
YoY :
-30.19%
215.00M
Net Income after Tax
FY2025Q2
YoY :
-28.57%
0.75
EPS - Diluted
FY2025Q2
YoY :
-53.48%
107.00M
Free Cash Flow
FY2025Q2
YoY :
-2.94%
52.82
Gross Profit Margin - %
FY2025Q2
YoY :
-23.10%
17.94
FCF Margin - %
FY2025Q2
YoY :
-34.17%
12.89
Net Margin - %
FY2025Q2
YoY :
-10.63%
13.70
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 19490.71% over the last month.
Sold
0-3
Months
178.0K
USD
2
3-6
Months
444.5K
USD
2
6-9
Months
286.6K
USD
1
0-12
Months
2.5M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
103.1K
Volume
3
6-9
Months
144.8K
Volume
7
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
1.5M
Volume
Months
6-9
9
2.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
40.5K
USD
2
3-6
Months
105.0K
USD
7
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
24.0K
USD
Months
3-6
2
65.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
8.0K
USD
Months
Insider
Insiders areSelling! The selling amount has increased 19490.71% over the last month.
Sold
0-3
Months
178.0K
USD
2
3-6
Months
444.5K
USD
2
6-9
Months
286.6K
USD
1
0-12
Months
2.5M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
A News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
06:02:29
West Pharmaceutical appoints Robert McMahon as CFO

2025-07-15 (ET)
2025-07-15
08:38:25
Agilent CFO Bob McMahon to step down

2025-05-30 (ET)
2025-05-30
08:48:57
Agilent removed from 'Tactical Outperform' list at Evercore ISI

Sign Up For More Events
Sign Up For More Events
News
9.5
07-17NewsfilterAgilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27
8.0
07-15WSJInside One Company’s Prolonged Tariff Limbo
3.0
07-08CNBCHere are buy levels for 3 stocks with big rallies since April's Trump tariff lows
Sign Up For More News
People Also Watch

NWG
NatWest Group PLC
14.035
USD
-0.32%

ODFL
Old Dominion Freight Line Inc
148.110
USD
+1.13%

TAK
Takeda Pharmaceutical Co Ltd
13.810
USD
+1.54%

LHX
L3Harris Technologies Inc
273.860
USD
-0.09%

GRMN
Garmin Ltd
218.510
USD
-1.35%

AMX
America Movil SAB de CV
18.140
USD
0.00%

EW
Edwards Lifesciences Corp
80.140
USD
-1.26%

CBRE
CBRE Group Inc
157.760
USD
+0.25%

AME
AMETEK Inc
185.200
USD
+4.77%

HLN
Haleon PLC
9.480
USD
-1.66%
FAQ

What is Agilent Technologies Inc (A) stock price today?
The current price of A is 116.89 USD — it has decreased -0.98 % in the last trading day.

What is Agilent Technologies Inc (A)'s business?

What is the price predicton of A Stock?

What is Agilent Technologies Inc (A)'s revenue for the last quarter?

What is Agilent Technologies Inc (A)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Agilent Technologies Inc (A)'s fundamentals?

How many employees does Agilent Technologies Inc (A). have?
